Lauren Jennifer MacKenzie

Dr. Lauren Jennifer MacKenzie

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2020 in Annals of Internal Medicine
Verified
Journal Article
Open access
CSCaleb Skipper
Caleb Skipper
KPKatelyn A. Pastick
Katelyn A. Pastick
NENicole W. Engen
Nicole W. Engen
ABAnanta S. Bangdiwala
Ananta S. Bangdiwala
MAMahsa Abassi
Mahsa Abassi
DBDavid Boulware
David Boulware
There is no known effective oral therapy for early COVID-19. This randomized trial evaluated effects of oral hydroxychloroquine on symptoms and disease severity in adult outpatients with early COVI... Visual Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 There is no known effective oral therapy for early COVID-19. This randomized, double-blind, placebo-controlled trial... Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19). Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients....

1 May 2017 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
KSKatherine R Schafer
Katherine R Schafer
HAHelmut Albrecht
Helmut Albrecht
RDRebecca Dillingham
Rebecca Dillingham
RHRobert S Hogg
Robert S Hogg
DJDenise Jaworsky
Denise Jaworsky
MOMichael E Ohl
Michael E Ohl
The nature of the HIV epidemic in the United States and Canada has changed with a shift toward rural areas. Socioeconomic factors, geography, cultural context, and evolving epidemics of injection drug use are coalescing to move the epidemic into locations where populations are dispersed and health care resources are limited. Rural–urban differences along the care continuum demonstrate the implications of this sociogeographic shift. Greater attention is needed to build a more comprehensive understanding of the rural HIV epidemic in the United States and Canada, including research efforts, innovative approaches to care delivery, and greater community engagement in prevention and care.

1 December 2006 in Journal of Proteome Research
Verified
Journal Article
Closed access
NWNan Wang
Nan Wang
LMLauren Jennifer MacKenzie
Lauren Jennifer MacKenzie
ASAndrea G. De Souza
Andrea G. De Souza
HZHongying Zhong
Hongying Zhong
GGGreg Goss
Greg Goss
LLLiang Li
Liang Li

10 September 2015 in AIDS
Verified
Journal Article
Closed access
VLViviane D. Lima
Viviane D. Lima
ARAnja Reuter
Anja Reuter
PHP. Richard Harrigan
P. Richard Harrigan
LLLillian Lourenço
Lillian Lourenço
WCWilliam Chau
William Chau
JMJulio S.G. Montaner
Julio S.G. Montaner
Objective: There is limited research investigating the possible mechanisms of how starting combination antiretroviral therapy (cART) at a higher CD4+ cell count decreases mortality. This study investigated the association between initiating cART with short-term and long-term achievement of viral suppression; emergence of any drug resistance and of an AIDS-defining illness (ADI); long-term treatment adherence; and all-cause mortality. Methods: This retrospective cohort study included 4120 naive patients who initiated cART between 2000 and 2012. Patients were followed until 2013, death or until the last contact date (varied by outcome). The main exposure was the interaction between period of cART initiation (2000–2006 and 2007–2012) and CD4+ cell count at cART initiation (<500 versus ≥500 cells/μl). We considered both baseline and longitudinal covariates. We fitted different multivariable models using cross-sectional and longitudinal statistical methods, depending on the outcome. Results: Patients who initiated cART with a CD4+ cell count at least 500 cells/μl in 2007–2012 had an increased likelihood of achieving viral suppression at 9 months and of maintaining an adherence level of at least 95% over time, and the lowest probability of developing any resistance and an ADI during follow-up. These patients were not the ones with the highest likelihood of maintaining viral suppression over time, most likely due to viral load blips experienced during the follow-up. Conclusion: The outcomes in this study likely play an important role in explaining the positive impact of early cART initiation on mortality. These results should alleviate some of the concerns clinicians may have when initiating cART in patients with high CD4+s as recommended by current treatment guidelines.

21 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RRRadha Rajasingham
Radha Rajasingham
ABAnanta S Bangdiwala
Ananta S Bangdiwala
MNMelanie R Nicol
Melanie R Nicol
CSCaleb Skipper
Caleb Skipper
KPKatelyn A Pastick
Katelyn A Pastick
SLSarah M Lofgren
Sarah M Lofgren
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging virus causing the ongoing Covid-19 pandemic with no known effective prophylaxis. We investigated whether hydroxychloroquine could prevent SARS CoV-2 in healthcare workers at high-risk of exposure. Methods: We conducted a randomized, double-blind, placebo-controlled clinical trial of healthcare workers with ongoing exposure to persons with Covid-19, including those working in emergency departments, intensive care units, Covid-19 hospital wards, and first responders. Participants across the United States and in the Canadian province of Manitoba were randomized to hydroxychloroquine 400mg once weekly or twice weekly for 12 weeks. The primary endpoint was confirmed or probable Covid-19-compatible illness. We measured hydroxychloroquine whole blood concentrations. Results: We enrolled 1483 healthcare workers, of which 79% reported performing aerosol-generating procedures. The incidence of Covid-19 (laboratory-confirmed or symptomatic compatible illness) was 0.27 events per person-year with once-weekly and 0.28 events per person-year with twice-weekly hydroxychloroquine compared with 0.38 events per person-year with placebo. For once weekly hydroxychloroquine prophylaxis, the hazard ratio was 0.72 (95%CI 0.44 to 1.16; P=0.18) and for twice weekly was 0.74 (95%CI 0.46 to 1.19; P=0.22) as compared with placebo. Median hydroxychloroquine concentrations in whole blood were 98 ng/mL (IQR, 82-120) with once-weekly and 200 ng/mL (IQR, 159-258) with twice-weekly dosing. Hydroxychloroquine concentrations did not differ between participants who developed Covid-19 (154 ng/mL) versus participants without Covid-19 (133 ng/mL; P=0.08). Conclusions: Pre-exposure prophylaxis with hydroxychloroquine once or twice weekly did not significantly reduce laboratory-confirmed Covid-19 or Covid-19-compatible illness among healthcare workers. Key Points: In this randomized clinical trial of 1483 high-risk healthcare workers, there was no significant reduction in incidence of Covid-19 with once weekly or twice weekly hydroxychloroquine compared to placebo.

1 January 2018 in IDCases
Verified
Journal Article
Open access
KUKelsey Uminski
Kelsey Uminski
KKKamran Kadkhoda
Kamran Kadkhoda
BHBrett L. Houston
Brett L. Houston
ALAlison Lopez
Alison Lopez
LMLauren Jennifer MacKenzie
Lauren Jennifer MacKenzie
RZRyan Zarychanski
Ryan Zarychanski
Human Granulocytic Anaplasmosis (HGA) is an infection caused by the intracellular bacterium Anaplasma phagocytophilum. As a tick-borne disease, the public health impact of HGA continues to increase with range expansion of the disease vector. The clinical presentation of HGA is often a non-specific febrile illness. The presence of leukopenia, thrombocytopenia, and mild hepatic injury are frequently noted on laboratory investigations, which can be important diagnostic clues in attaining an appropriate diagnosis. Herein we present three cases of HGA, highlighting the spectrum of disease by which HGA can manifest. Although each case has their unique features, we outline important shared clinical elements to facilitate an empiric diagnosis while definitive laboratory investigations are pending. Our case series further serves to highlight the critical importance of prompt antimicrobial treatment to reduce morbidity and potential mortality.